The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems ...

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...

Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus (CMV) vaccine candidate, mRNA-1647.

Mixed options sentiment in Moderna (MRNA), with shares down 50c near $26.36. Options volume relatively light with 22k contracts traded and puts ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Small study looks only at a cardiac biomarker; findings are in line with reduced myocarditis risk in mRNA COVID vaccines ...

Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.

A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and shingles can succeed after the failure of the CMV program.

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

But more quietly, the company is still moving forward with its pipeline, including cancer and rare disease therapeutics. The ...

Key opinion leaders previously interviewed by GlobalData noted the need for more data on current RSV vaccines and their use ...